Short answer
Scientific studies of ayahuasca provide preliminary data on pharmacology, short-term state changes, and possible associations with mental well-being. However, the evidence base is heterogeneous: controlled trials are few, samples are often small, composition of decoctions varies, and long-term follow-up is limited. Current results form research hypotheses, but do not confirm universal or guaranteed benefit. Each finding should be read in conjunction with the design, sample, and follow-up period.
How to make sense of the research
The question "has ayahuasca been studied" is too broad. One study may measure molecules in the laboratory, another - changes in the indicator after a day, a third - memories of participants years later. They are all scientific, but they answer different questions and differ in how well they can establish cause and effect.
Reliability of the conclusion is determined not by how striking the result sounds, but by the design of the study. The method of recruitment, comparison group, blinding, sample size, predefined measures, and duration of follow-up are important. The result for a few dozen selected volunteers cannot be automatically transferred to the wider population.
It is useful to distinguish three levels: what happens to substances in the body; what people report under controlled conditions; what is observed in real-world settings. The material about the mechanism of action of ayahuasca explains the basic interaction of the components.
Preclinical and pharmacological data
Pharmacological reviews describe DMT and the β-carboline alkaloids of harmala as components with different pharmacokinetics. Some of the β-carbolines temporarily inhibit the enzyme monoamine oxidase A, which alters the availability of DMT after oral administration. This explains a possible biological mechanism, but does not predict the full human response.
The composition of different samples is not the same. Plant species, concentrations and ratios of substances vary; laboratory-standardized material is not identical to an unknown decoction. Therefore, the exact analysis of one sample does not establish the properties of all that is called ayahuasca.
Mechanism is an explanation of the possibility of an effect, not proof of a beneficial outcome. Receptor binding or cellular results may justify the next stage of validation. They do not show whether a person's daily functioning will improve or how long the change will last.
Controlled laboratory studies involving humans
Laboratory work with healthy volunteers helps to describe acute subjective and physiological reactions in a more controlled environment. Researchers can record the time of onset of effects, blood pressure, pulse, nausea, changes in perception, and questionnaire scores.
The strength of this design is more precise control of conditions. Its limitations include selective recruitment, a short follow-up period and a setting that differs from a group ceremony. Healthy volunteers without certain risk factors do not represent all people interested in the topic.
Blinding is also difficult: pronounced subjective effects can tell the participant and the researcher which group they fall into. This reinforces expectations and can affect self-reported ratings. Active placebo and independent evaluation help, but do not eliminate the problem completely.
Small clinical trials
A randomized placebo-controlled trial included 29 people with treatment-resistant depression. After one session, depression scores on the MADRS scale were lower in the ayahuasca group on days 1, 2 and 7. This preliminary result does not establish lasting benefit.
The sample size of 29 participants does not establish sustained efficacy or outcome for everyone. Single-center design, short evaluation period, difficulty in blinding, and selective recruitment limit how broadly the findings can be applied. Larger independent trials with longer follow-up are needed.
A placebo-controlled field study of 30 experienced participants revealed changes in some indicators in the placebo group as well. Natural conditions are interesting, but the small sample and previous experience make it difficult to separate the effects of different aspects of the setting. Together, these works remind us that expectation and environment are part of the observed outcome.
Observational and naturalistic studies
Naturalistic studies observe people in conditions where the event would have occurred without the research team. This gives a more realistic picture and allows you to ask questions about changes after weeks or months. At the same time, the participants themselves choose to participate, and there is often no control group.
Longitudinal work with 53 participants reported changes in indicators after one month. A before-and-after measurement is stronger than a one-time survey, but does not rule out expectations, parallel life changes, regression to the mean, or characteristics of the people who consented to follow-up.
Large international online surveys cover thousands of responses and show a diversity of experiences. However, they rely on self-report, memory, and self-selection. The association between participation and well-being does not show what exactly caused the difference. People may have differed before the event or received other supports at the same time.
Data on unwanted and long-term effects
Short controlled studies are better at capturing common acute reactions than rare or delayed events. Their selection criteria may exclude people at increased risk, and the small sample size prevents reliable assessment of rare effects.
Self-report studies in a religious or retreat context describe temporary physical reactions and unwanted mental states among respondents. A re-analysis of the Global ayahuasca Survey linked previous anxiety or depression with more adverse experiences. This correlation alone cannot establish whether the difficulties resulted from the experience or reflected pre-existing vulnerability.
A systematic review of adverse events in clinical trials of classic psychedelics found inconsistent reporting. For ayahuasca, the problem is more complicated due to differences in composition and context. A detailed overview is collected in the safety and risks article.
What systematic reviews add
A systematic review collects papers according to predefined rules, assesses their quality, and shows where the results agree. It does not eliminate weaknesses in the underlying data: if most works are small and observational, the review can only summarize the evidence available.
An early review of human studies described promising signals but highlighted heterogeneity and the need for better controlled studies. A more recent review of 18 prospective studies of long-term outcomes also found signs of change, while noting small sample sizes, a predominance of retreat volunteers, nonstandardized design, and frequent lack of controls.
A review shows both what the studies found and how strong the evidence is. The number of publications does not equal the number of independent confirmations: a single cohort can appear in several articles, and positive results are published more readily than neutral ones.
Why the results of different works do not always coincide
A discrepancy does not necessarily mean that one team was wrong. Researchers can recruit people with different prior experiences, use different exclusion criteria, compare dissimilar cohorts, and measure outcome at different time points. A measurement after one day, an assessment after a week and daily functioning after six months capture different stages.
What is chosen as the main result is also important. Reduction in mean symptom scale score, proportion of people with clinically significant change, sleep quality, and return to usual duties are not interchangeable. If the news mentions only one positive indicator, it is worth looking at how many indicators were analyzed in total and whether this result was determined in advance.
Differences may occur due to loss of participants to follow-up. People who experienced difficulties or saw little reason to continue may be more likely to miss follow-up questionnaires. Then the final sample looks more positive than the initial one. A well-reported publication shows how many people dropped out, for what reasons, and how this was accounted for in the analysis.
Equally important is independent replication. Replication of the result by a different team, in a different center and in a new sample reduces the likelihood that the conclusion reflects chance or local conditions. It is repetition that gradually transforms an interesting signal into more reliable knowledge.
Quality of evidence and major limitations
The evidence can be summarized cautiously: there is a biologically plausible mechanism, preliminary findings from controlled studies, and numerous observational associations, but there is not a sufficient body of large independent studies to draw broad conclusions. Rare effects, long-term results, and differences between specific formulations are particularly poorly described.
While reading, you should check:
- how many people started and finished the study;
- how participants were recruited and who was excluded;
- whether there was a control group and how effective blinding was;
- what material was studied and whether the composition was standardized;
- when the result was measured - after hours, weeks or months;
- whether indicators were defined prior to analysis and whether adverse events were reported.
It is important to distinguish between statistical and clinical significance. Even a reliable mean change score does not explain how many people experienced a marked benefit, how many did not respond, and what side effects occurred in parallel.
Open questions for future research
Multicenter trials with larger sample sizes, active controls, independent teams, and longer follow-up are needed. Consistent definitions of adverse events, registration of protocols before recruitment, and publication of neutral outcomes would be helpful.
A separate question is the role of context. Future work should more accurately describe psychological support, expectations, group experiences, and post-session events. Without this, it is difficult to understand what is related to pharmacology and what is related to the environment or a combination of the two.
Preliminary findings need to be tested and replicated. A well-written account states precisely what is known, for whom, under what conditions, and over what time. The limits of personal testimony are discussed separately in the article about ayahuasca experience.
Sources
- Randomized placebo-controlled trial involving 29 people.
- Placebo-controlled field study involving 30 people.
- Systematic review of early human studies.
- Systematic review of 18 prospective studies of long-term outcomes.
- Naturalistic longitudinal study of 53 participants.
- International Cross-sectional Survey of Mental Health and Well-Being.
- Re-analysis of adverse mental states in the Global ayahuasca Survey.
- Systematic Review of Adverse Event Reporting.